World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 14 November 2016
Main ID:  NCT01225393
Date of registration: 18/10/2010
Prospective Registration: Yes
Primary sponsor: Genentech, Inc.
Public title: A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
Scientific title: A Phase II, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patient With Active Rheumatoid Arthritis
Date of first enrolment: November 2010
Target sample size: 211
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT01225393
Study type:  Interventional
Study design:  Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment  
Phase:  Phase 2
Countries of recruitment
Bulgaria Chile Germany Hungary Mexico Peru Poland Romania
Spain United States
Contacts
Name:     John C. Davis, Jr., M.D., M.P.H.
Address: 
Telephone:
Email:
Affiliation:  Genentech, Inc.
Key inclusion & exclusion criteria

Inclusion Criteria:

- Diagnosis of RA according to the 1987 revised ACR Criteria for the Classification of
RA for at least 6 months prior to screening

- Positive for rheumatoid factor or anti-cyclic citrullinated peptide (CCP) antibody,
or both

- Active disease, defined as: CRP >= 1.0 mg/dL; swollen joint count >= 6 (66 joint
count); tender joint count >= 6 (68 joint count)

- Previous inadequate clinical response to at least one disease-modifying
anti-rheumatic drug (DMARD) consisting of either methotrexate (MTX) or leflunomide
(LFU)

- For patients currently receiving corticosteroids: Treatment at a stable dose during
last 4 weeks prior to screening

- For patients currently receiving non-steroidal anti-inflammatory drugs (NSAIDs):
Treatment at a stable dose during last 4 weeks prior to screening

- For patients currently receiving sulfasalazine or anti-malarials: Treatment initiated
and continued for at least the last 6 months prior to screening and on a stable dose

- For patients of reproductive potential (males and females): Willing to use a highly
effective birth control method for the duration of the study according to local
guidelines

Exclusion Criteria:

- Pregnant, planning to become pregnant during the study, or breastfeeding

- Clinically significant abnormal laboratory values or abnormal ECG or vital signs

- History of anaphylactic reactions

- Rheumatic autoimmune disease other than RA, or significant systemic involvement
secondary to RA (including but not limited to vasculitis, pulmonary fibrosis, or
Felty's syndrome), however patients with secondary Sjogren's syndrome are eligible
for the study

- History of or current inflammatory joint disease other than RA (e.g., gout, reactive
arthritis, psoriatic arthritis, seronegative spondyloarthritis, Lyme disease) or
other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory
bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease,
or other overlap syndrome)

- Current or recent (within 4 weeks prior to screening) infection, including signs,
symptoms or serology of any infection, including HIV, hepatitis B or C, tuberculosis

- Administration of a live, attenuated vaccine within 1 month before dosing or
anticipation that such a live attenuated vaccine will be required during the study

- Previous treatment with anti-TNF biologics or other biologic agents, including
anti-CD20-directed therapy (e.g. rituximab), anti-IL6-directed therapy (e.g.
tocilizumab), or T cell-directed therapy (e.g. abatacept)



Age minimum: 18 Years
Age maximum: 75 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis
Intervention(s)
Drug: placebo
Drug: methotrexate
Drug: adalimumab
Drug: leflunomide
Drug: MLTA3698A
Primary Outcome(s)
Baseline change in disease activity, assessed as the Disease Activity Score (DAS28) and erythrocyte sedimentation rate, or DAS28-(4)-ESR [Time Frame: Day 85]
Incidence and severity of adverse events and clinical laboratory abnormalities as a measure of safety and tolerability of MLTA3698A [Time Frame: Length of study (through Day 85)]
Secondary Outcome(s)
ACR20 response rate (the proportion of patients in each treatment group meeting the American College of Rheumatology 20% responder criteria [ACR20] for their average response ) [Time Frame: Day 85]
ACR50 response rate (the proportion of patients in each treatment group meeting the American College of Rheumatology 50% responder criteria [ACR50] for their average response ) [Time Frame: Day 85]
Serum C-reactive protein levels [Time Frame: Day 85]
Health Assessment Questionnaire Disability Index [Time Frame: Day 85]
Tender joint count [Time Frame: Day 85]
Investigator Global Assessment of Disease Activity [Time Frame: Day 85]
ACR70 response rate (the proportion of patients in each treatment group meeting the American College of Rheumatology 70% responder criteria [ACR70] for their average response) [Time Frame: Day 85]
European League Against Rheumatism response rate [Time Frame: Day 85]
Patient Global Assessment of Pain and Disease Activity [Time Frame: Day 85]
Patient's Global Health or Short Form Health Survey (SF-36) [Time Frame: Day 85]
Swollen joint count [Time Frame: Day 85]
Erythrocyte sedimentation rate [Time Frame: Day 85]
Secondary ID(s)
ALT4864g
GA00932
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey